The future of pulsed field ablation (PFA) technology could go in the direction of high-voltage nanosecond energy bursts, ...

In patients with persistent atrial fibrillation, those receiving pulsed field ablation as first-line therapy had less risk ...

Adagio Medical (Nasdaq:ADGM) today announced new six-month results from its FULCRUM-VT clinical trial evaluating its ablation ...

Johnson & Johnson said Friday it has struck a deal to buy Atraverse Medical, an atrial fibrillation ablation device developer ...

Treatment success with pulsed field ablation was higher at 1 year than with antiarrhythmic drug therapy for patients with persistent atrial fibrillation.

A major clinical trial has found Boston Scientific’s Farapulse pulsed-field ablation nearly doubles the success rate of treating persistent atrial fibrillation compared with medication. One year after ...

Rhythm (Nasdaq:IRTC) today announced findings from two real-world analyses supporting its long-term heart monitoring ...

Should the transaction complete, J&J will inherit Atraverse’s radiofrequency system for simplifying access to the heart’s left atrium.

J&J Medtech has launched the latest version of its pulsed ablation device after receiving CE Mark approval in Europe. The Varipulse Pro is touted by the company as improving the process of the ...

Ablation therapy consists of a minimally invasive treatment, which can be used for treating cancer by destroying tumors and other abnormal tissues within the body. It uses either extremely high or low ...

Pulsed field ablation (PFA), a technology now approved in Europe but not yet licensed in the United States, achieved noninferiority to conventional thermal ablation for the treatment of atrial ...

The US Food and Drug Administration’s (FDA) Center for Devices and Radiological Health (CDRH) issued draft guidance Tuesday to support clinical testing of high-intensity ultrasound systems for ...